Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Teprotumumab: First Approval.

Literature DB >> 32157641

Teprotumumab: First Approval.

Abstract

Teprotumumab (teprotumumab-trbw; TEPEZZA™ - Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated ophthalmopathy). Based on positive results from two multinational clinical trials teprotumumab was recently approved for this indication in the US. This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2020 PMID： 32157641 DOI： 10.1007/s40265-020-01287-y

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

2 in total

1. Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors: Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245

2. Teprotumumab for the Treatment of Active Thyroid Eye Disease.

Authors: Raymond S Douglas; George J Kahaly; Amy Patel; Saba Sile; Elizabeth H Z Thompson; Renee Perdok; James C Fleming; Brian T Fowler; Claudio Marcocci; Michele Marinò; Alessandro Antonelli; Roger Dailey; Gerald J Harris; Anja Eckstein; Jade Schiffman; Rosa Tang; Christine Nelson; Mario Salvi; Sara Wester; Jeffrey W Sherman; Thomas Vescio; Robert J Holt; Terry J Smith
Journal: N Engl J Med Date: 2020-01-23 Impact factor: 91.245

2 in total

13 in total

1. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.

Authors: Roshini Fernando; Terry J Smith
Journal: J Clin Endocrinol Metab Date: 2022-09-28 Impact factor: 6.134

Review 2. 2021 update on thyroid-associated ophthalmopathy.

Authors: E J Neag; T J Smith
Journal: J Endocrinol Invest Date: 2021-08-20 Impact factor: 5.467

Review 3. New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine.

Authors: Qiongyao He; Hui Dong; Minmin Gong; Yujin Guo; Qingsong Xia; Jing Gong; Fuer Lu
Journal: Front Pharmacol Date: 2022-04-05 Impact factor: 5.988

Teprotumumab: First Approval.

1. Teprotumumab for Thyroid-Associated Ophthalmopathy.

2. Teprotumumab for the Treatment of Active Thyroid Eye Disease.

1. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.

Review 2. 2021 update on thyroid-associated ophthalmopathy.

Review 3. New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine.

4. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.

Review 5. Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug.

6. Teprotumumab: a disease modifying treatment for graves' orbitopathy.

Review 7. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.

8. Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab.

9. Teprotumumab for thyroid eye disease: early response is not required for benefit.

Review 10. Insulin-Like Growth Factor Pathway and the Thyroid.